Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents
Daihiko Hakuno, … , Satoshi Ogawa, Keiichi Fukuda
Daihiko Hakuno, … , Satoshi Ogawa, Keiichi Fukuda
Published June 14, 2010
Citation Information: J Clin Invest. 2010;120(7):2292-2306. https://doi.org/10.1172/JCI40973.
View: Text | PDF | Corrigendum
Research Article

Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents

  • Text
  • PDF
Abstract

Valvular heart disease (VHD) is the term given to any disease process involving one or more of the heart valves. The condition can be congenital or acquired, for example as a result of atherosclerosis or rheumatic fever. Despite its clinical importance, the molecular mechanisms underlying VHD remain unknown. We investigated the pathophysiologic role and molecular mechanism of periostin, a protein that plays critical roles in cardiac valve development, in degenerative VHD. Unexpectedly, we found that periostin levels were drastically increased in infiltrated inflammatory cells and myofibroblasts in areas of angiogenesis in human atherosclerotic and rheumatic VHD, whereas periostin was localized to the subendothelial layer in normal valves. The expression patterns of periostin and chondromodulin I, an angioinhibitory factor that maintains cardiac valvular function, were mutually exclusive. In WT mice, a high-fat diet markedly increased aortic valve thickening, annular fibrosis, and MMP-2 and MMP-13 expression levels, concomitant with increased periostin expression; these changes were attenuated in periostin-knockout mice. In vitro and ex vivo studies revealed that periostin promoted tube formation and mobilization of ECs. Furthermore, periostin prominently increased MMP secretion from cultured valvular interstitial cells, ECs, and macrophages in a cell type–specific manner. These findings indicate that, in contrast to chondromodulin I, periostin plays an essential role in the progression of cardiac valve complex degeneration by inducing angiogenesis and MMP production.

Authors

Daihiko Hakuno, Naritaka Kimura, Masatoyo Yoshioka, Makio Mukai, Tokuhiro Kimura, Yasunori Okada, Ryohei Yozu, Chisa Shukunami, Yuji Hiraki, Akira Kudo, Satoshi Ogawa, Keiichi Fukuda

×

Figure 1

Periostin isoforms are specifically expressed in the cardiac valves and annuli of embryonic and adult rodent hearts.

Options: View larger image (or click on image) Download as PowerPoint
Periostin isoforms are specifically expressed in the cardiac valves and ...
(A and B) RT-PCR (A) and Western blot (B) analyses of periostin isoforms in the mouse heart. The primer pair 1 for murine periostin (A, right) was used for PCR. Each box in the C-terminal (CT) domain represents an exon. Single and double asterisks represent the long and short periostin isoforms, respectively. Periostin was first detected in the hearts at E8.5, and the relative expression level of this protein decreased postnatally. MC3T3-E1 cells are a positive control. M, marker; FAS1, fasciclin I domain. (C) RT-PCR (top) and Western blot (bottom) analyses of the periostin isoforms in adult mouse cardiac valves (CV). AV, aortic valve; MV, mitral valve. (D and E) Immunostaining for periostin in the hearts of mice at E11.5 to 4 weeks of age (D) and in the heart of a 6-week-old rat (E). In D, periostin was specifically expressed in the outflow tract (OFT), cardiac valves, and annuli (arrows). In E, periostin (brown) was expressed in all 4 cardiac valves and their annuli. The boxed regions are shown at higher magnification. Note that periostin was localized to the subendothelial superficial layer of the adult cardiac valve. AML, anterior mitral leaflet; Ao, aorta; IVS, interventricular septum; LA, left atrium; PML, posterior mitral leaflet; PV, pulmonary valve; RA, right atrium; TV, tricuspid valve. Scale bars: 200 μm (D); 50 μm (D, higher magnification); 500 μm (E); 20 μm (E, higher magnification).
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts